184 related articles for article (PubMed ID: 983808)
1. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.
Strandberg I; Boman G; Hassler L; Sjöqvist F
Acta Med Scand; 1976; 200(5):367-71. PubMed ID: 983808
[TBL] [Abstract][Full Text] [Related]
2. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility.
Batchelor JR; Welsh KI; Tinoco RM; Dollery CT; Hughes GR; Bernstein R; Ryan P; Naish PF; Aber GM; Bing RF; Russell GI
Lancet; 1980 May; 1(8178):1107-9. PubMed ID: 6103441
[TBL] [Abstract][Full Text] [Related]
3. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
4. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
[TBL] [Abstract][Full Text] [Related]
5. Clinical consequences of polymorphic acetylation of basic drugs.
Drayer DE; Reidenberg MM
Clin Pharmacol Ther; 1977 Sep; 22(3):251-8. PubMed ID: 19187
[TBL] [Abstract][Full Text] [Related]
6. Hydrallazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype.
Harland SJ; Facchini V; Timbrell JA
Br Med J; 1980 Jul; 281(6235):273-4. PubMed ID: 7427242
[No Abstract] [Full Text] [Related]
7. Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype.
Russell GI; Bing RF; Jones JA; Thurston H; Swales JD
Q J Med; 1987 Oct; 65(246):845-52. PubMed ID: 3329739
[TBL] [Abstract][Full Text] [Related]
8. Cadralazine challenge in patients with previous hydralazine-induced lupus: a 6-month study.
Pålsson L; Weiner L; Englund G; Henning M
Clin Pharmacol Ther; 1989 Aug; 46(2):177-81. PubMed ID: 2758727
[TBL] [Abstract][Full Text] [Related]
9. Acetylator phenotype and lupus erythematosus.
Uetrecht JP; Woosley RL
Clin Pharmacokinet; 1981; 6(2):118-34. PubMed ID: 7011656
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous systemic lupus erythematosus and acelylator phenotype.
Larsson R; Karlsson E; Molin L
Acta Med Scand; 1977; 201(3):223-6. PubMed ID: 848361
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of immunologic effects of hydralazine in hypertensive patients.
Litwin A; Adams LE; Zimmer H; Foad B; Loggie JH; Hess EV
Clin Pharmacol Ther; 1981 Apr; 29(4):447-56. PubMed ID: 6970646
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.
Horai Y; Ishizaki T; Sasaki T; Koya G; Matsuyama K; Iguchi S
Br J Clin Pharmacol; 1982 Mar; 13(3):361-74. PubMed ID: 7059436
[TBL] [Abstract][Full Text] [Related]
13. Hydralazine, antinuclear antibodies, and the lupus syndrome.
Mansilla-Tinoco R; Harland SJ; Ryan PJ; Bernstein RM; Dollery CT; Hughes GR; Bulpitt CJ; Morgan A; Jones JM
Br Med J (Clin Res Ed); 1982 Mar; 284(6320):936-9. PubMed ID: 6802356
[TBL] [Abstract][Full Text] [Related]
14. Acetylator phenotype and the antihypertensive response to hydralazine.
Jounela AJ; Pasanen M; Mattila MJ
Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
[TBL] [Abstract][Full Text] [Related]
15. Hydralazine and lupus nephritis.
Ihle BU; Whitworth JA; Dowling JP; Kincaid-Smith P
Clin Nephrol; 1984 Nov; 22(5):230-8. PubMed ID: 6240359
[TBL] [Abstract][Full Text] [Related]
16. Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus.
Morris RJ; Freed CR; Kohler PF
Arthritis Rheum; 1979 Jul; 22(7):777-80. PubMed ID: 454504
[TBL] [Abstract][Full Text] [Related]
17. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide.
Sonnhag C; Karlsson E; Hed J
Acta Med Scand; 1979; 206(4):245-51. PubMed ID: 92167
[TBL] [Abstract][Full Text] [Related]
18. Drug acetylation and expression of lupus erythematosus.
Marsden JR; Mason GG; Coburn PR; Rawlins MD; Shuster S
Eur J Clin Pharmacol; 1985; 28(4):387-90. PubMed ID: 4029245
[TBL] [Abstract][Full Text] [Related]
19. Immunologic effects of hydralazine in hypertensive patients.
Litwin A; Adams LE; Zimmer H; Hess EV
Arthritis Rheum; 1981 Aug; 24(8):1074-8. PubMed ID: 6974554
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
